Get started
Author

Mackenzie Jordan

The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial
2023 · Sabashini K. Ramchand, Joy N. Tsai, et al. · Osteoporosis International · 24
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
2026 · Benjamin Z Leder, Sabashini K Ramchand, et al. · The Lancet Diabetes & Endocrinology · 17
One versus 2 years of alendronate following denosumab: the CARD extension
2024 · Joy N. Tsai, Mackenzie Jordan, et al. · Osteoporosis International · 10
Treatment of Children and Adults With X-Linked Hypophosphatemia With Calcitriol Alone: A Prospective, Open-Label Study
2025 · Deborah Mitchell, Mackenzie Jordan, et al. · The Journal of Clinical Endocrinology & Metabolism · 1
The comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength
2025 · Benjamin Z Leder, Joy N Tsai, et al. · JBMR Plus
PDF
Three Versus Twelve Months of Romosozumab for Postmenopausal Osteoporosis: An Open Label Randomised Controlled Trial. The Limited Duration Anabolic Therapy (LIDA) Study
2025 · Benjamin Z. Leder, Sabashini K. Ramchand, et al. · SSRN Electronic Journal
Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial
2023 · Sabashini K. Ramchand, Joy N. Tsai, et al. · Osteoporosis International
PDF
Works count: 7
Citation count: 52
H-index: 3
I10-index: 3
Year
Topic
Type